• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Abeona Therapeutics - Articles and news items

epidermolysis-abeona

Abeona enrols first Phase 2 patient following successful Phase 1 Epidermolysis trial

Industry news / 27 September 2016 / Niamh Louise Marriott, Digital Content Producer

Also known as “Butterfly skin” syndrome, epidermolysis bullosa (EB) is a rare genetic skin disease that is caused by the absence of a gene (COL7A1)…

epidermolysis-abeona

Abeona enrols 5th patient in gene therapy Epidermolysis Bullosa trial

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

EB-101 is the company’s lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of…

cohort-trial-sanfilippo

Abeona Therapeutics completes cohort in Sanfilippo syndrome trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The first-in-man clinical trial utilises a single injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death…

Biopotency signals demonstrated in Sanfilippo type A Gene therapy trial, provides Abeona Therapeutics

Sanfilippo type A Gene therapy trial shows biopotency signals, provides Abeona Therapeutics

Industry news / 2 August 2016 / Abeona Therapeutics Inc

Abeona Therapeutics provides an update on its first Sanfilippo patient and reports that early biopotency signals suggest a reduction of heparan sulfate in the urine of patients and if confirmed will suggest that intravenous administration of ABO-102 may ultimately provide both central nervous system and systemic benefits to patients…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +